

# Alzheimer's disease and dementia: a new view of the brain



Advanced imaging technology  
offers new promise

# Alzheimer's disease and dementia: a new view of the brain



This clinical breakthrough is made possible by a new comprehensive amyloid imaging solution combining a radiopharmaceutical, proprietary neurology quantification software,<sup>1</sup> and PET•CT imaging with the Biograph mCT family of scanners from Siemens.

This comprehensive solution helps physicians to visualize amyloid protein deposits in the brain. In a healthy brain, these deposits are broken down and eliminated. In patients with Alzheimer's disease, the amyloid protein deposits accumulate over time to form hard plaques that build up between cells in the brain. Since these plaques do not build up in the same way in the brains of people with other forms of dementia, it is now possible to use these images in combination with other diagnostic tools to make a more confident evaluation of a patient's disease state.

**For the first time, your patients can receive advanced noninvasive brain imaging that can aid in the evaluation of amyloid plaques — a characteristic feature of Alzheimer's disease — in the living brain.**



1. syngo®.PET Amyloid Plaque is intended for use only with approved amyloid radiopharmaceuticals in the country of use. Users should review the drug labeling for approved uses.

This new imaging solution holds great promise for the evaluation of Alzheimer's disease and other forms of dementia. The symptoms of non-Alzheimer's dementia may potentially be treated and, in some cases, reversed.

If Alzheimer's disease is suspected, proper evaluation allows patients and their loved ones and caregivers more time to explore available treatment options, investigate clinical trials, and plan ahead for critical matters such as financial decisions and health care options.



### **It's a critical time to explore new options to assess Alzheimer's.**

Alzheimer's is now the sixth leading cause of death in the U.S., and the number of people living with Alzheimer's worldwide may nearly triple by 2050.<sup>2</sup> Costs of caring for people with Alzheimer's and other dementias will soar from an estimated \$203 billion this year to a projected \$1.2 trillion per year by 2050.<sup>2</sup>

As the baby boomer population ages and life expectancies continue to increase, Alzheimer's has the potential to place a tremendous strain on the healthcare system over the next several decades. By focusing on the development of new diagnostic tools and treatment options, the medical community can help to address this serious challenge.

2. Alzheimer's Association, 2013 Alzheimer's Disease Facts and Figures, Alzheimer's & Dementia, Volume 9, Issue 2.





### **The Biograph mCT PET•CT family of scanners from Siemens provides additional benefits**

The Biograph mCT family of scanners not only provides accurate and reproducible quantification in PET•CT imaging; these systems also offer exceptional comfort for patients up to 500 pounds. With large, patient-friendly 78-cm bore openings, their open design and fast scan times help to improve patient comfort and may help patients feel less claustrophobic.

Additionally, the Biograph mCT family uses various innovative dose-reducing technologies to minimize patient exposure to radiation, and the system's fast scan times result in less patient motion, so image quality can be optimized.

